Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | IDH1 | O75874 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6997976 | 0.86 | LMNA (0.47) | LMNAGAAIDH1POLBHPGD | |
| SCHEMBL2592753 | 0.86 | LMNA (0.49) | LMNAGAAIDH1POLBHPGD | |
| SCHEMBL2115557 | 0.86 | IDH1 (0.50) | LMNAGAAIDH1POLBHPGD | |
| SCHEMBL7622128 | 0.86 | LMNA (0.46) | LMNAGAAPOLBHPGDHTT | |
| SCHEMBL7698140 | 0.86 | LMNA (0.44) | LMNAGAAIDH1POLBHPGD | |
| SCHEMBL15910022 | 0.82 | LMNA (0.61) | LMNAGAAIDH1POLBHPGD | |
| SCHEMBL3560853 | 0.82 | LMNA (0.43) | LMNAGAAIDH1POLBHPGD | |
| SCHEMBL15910031 | 0.80 | IDH1 (0.50) | LMNAGAAIDH1POLBHPGD | |
| SCHEMBL2115663 | 0.79 | LMNA (0.50) | LMNAGAAIDH1POLBHPGD | |
| SCHEMBL6998848 | 0.78 | IDH1 (0.54) | LMNAGAAIDH1POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506911-B2 | Reacting a 2-(1-hydroxyalkyl)-3-hydroxypyran-4(1H)one compound with benzaldehyde dimethyl acetal to form 8-oxo-4,8-dihydro-2-phenyl-4h(3,2-d)-m-dioxin, reacting it with an amine compound to form an intermediate, then reducing | BTG INTERNATIONAL LIMITED (GB) | 2003-01-14 | — | — | US | disclosed |
| EP-0984934-B1 | NOVEL ORALLY ACTIVE IRON (III) CHELATORS | BTG INTERNAT LTD COMPANY NO 26 (GB) | 2003-01-08 | — | — | EP | disclosed |
| US-6448273-B1 | SUCH AS 2,6-DIMETHOXYMETHYL-1-METHYL-3-BENZYLOXPYRIDIN-4(1H)-ONE; TREATING DISORDERS ASSOCIATED WITH IRON DISTRIBUTION AND IRON DEPENDANT PARASITES; REDUCED LEVELS OF ACTIVE AGENT; SELECTIVE TARGETING TO TISSUES AND LIVER; METABOLIC STABILITY | BTG INTERNATIONAL LIMITED (GB) | 2002-09-10 | — | — | US | disclosed |
| US-20020068758-A1 | Novel orally active iron (III) chelators | BTG INTERNATIONAL LIMITED. | 2002-06-06 | — | — | US | disclosed |
| US-6335353-B1 | 3-HYDROXYPYRIDIN-4-ONE DERIVATIVE; IRON DEFICIENCY ANEMIA AND THALASSEMIA TREATMENT | BTG INTERNATIONAL LIMITED (GB) | 2002-01-01 | — | — | US | disclosed |
| EP-0984934-A1 | NOVEL ORALLY ACTIVE IRON (III) CHELATORS | BTG INTERNATIONAL LIMITED (Company No. 2664412) (GB) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054138-A1 | NOVEL ORALLY ACTIVE IRON (III) CHELATORS | BTG INTERNATIONAL LIMITED (GB) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068758-A1 | Novel orally active iron (III) chelators | HAMP, HRH2, GRHPR | LMNA 2634/4885GAA 1367/4885IDH1 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.